- Home
- OIM vs VCRE Comparison
OIM vs VCRE Comparison
Compare OIM & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | OIM | VCRE |
|---|---|---|
| Founded | 2025 | N/A |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 364.0M | 332.9M |
| IPO Year | 2025 | 2026 |
Fundamental Metrics
Financial Performance| Metric | OIM | VCRE |
|---|---|---|
| Price | $10.12 | $11.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 66.5K | 6.2K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.96 | $10.50 |
| 52 Week High | $10.33 | $13.00 |
Technical Indicators
Market Signals| Indicator | OIM | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 41.46 |
| Support Level | $10.06 | $10.74 |
| Resistance Level | $10.33 | $11.59 |
| Average True Range (ATR) | 0.01 | 0.64 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 25.00 | 38.80 |
Price Performance
Historical ComparisonAbout OIM OneIM Acquisition Corp. Class A Ordinary Shares
OneIM Acquisition Corp is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.